ABP 692

Amgen's ABP 692 is a biosimilar candidate to ocrelizumab, marketed by Roche as Ocrevus for multiple sclerosis. Ocrevus is a B-cell depleting antibody that generated roughly $7.5B for Roche in 2024 [6], making it one of the largest single MS assets on the market. The Phase 3 comparability study NCT06700343 completed enrollment of 152 patients with relapsing-remitting MS and moved to active-not-recruiting status in July 2026 [1]. Primary readout is pharmacokinetic AUC (area under the curve, a measure of total drug exposure in the bloodstream over time) through Day 15 after the first infusion, benchmarked against both US and EU sourced Ocrevus [1]. Amgen is one of the most experienced biosimilar developers globally, with prior approvals including Amjevita (adalimumab), Mvasi (bevacizumab), Kanjinti (trastuzumab), and Riabni (rituximab) [2]. Amgen is not alone in this class: Samsung Bioepis, Sandoz, Biocad, and Celltrion all have ocrelizumab biosimilar programs in development, so the launch market will be crowded [11]. The primary Ocrevus US composition-of-matter protection is estimated to expire around 2029 (with EU protection around 2028) per public patent trackers [12], so timing lines up for a competitive biosimilar wave pending BLA acceptance and resolution of Roche's patent portfolio around formulation, dosing interval, and manufacturing.

Phase 3 comparability study, NCT06700343, active-not-recruiting as of the July 2026 ClinicalTrials.gov update after hitting the 152-patient enrollment target [1]. Biosimilars follow FDA's 351(k) abbreviated pathway rather than a traditional BLA, so standard designations like breakthrough therapy, fast track, and orphan drug do not apply. The regulatory bar is analytical, functional, PK, PD, and immunogenicity similarity to the reference product, not clinical superiority. PK/PD readouts from comparability studies typically come within 12 to 18 months of enrollment complete, which puts a plausible readout in late 2027. A 351(k) submission would follow. Under BsUFA III, FDA has a 10-month review goal from the 60-day filing decision for standard biosimilar applications, so total time from submission to action is roughly 12 months [13]. Amgen has not disclosed whether it will seek interchangeability status, which would allow pharmacy-level substitution without prescriber intervention. Given Ocrevus is a physician-administered infusion, interchangeability matters less than for self-administered biologics like adalimumab, where Amgen initially sold Amjevita without interchangeability and later added it [2]. Amgen has also not publicly confirmed a parallel EMA submission, though the three-way US-sourced vs EU-sourced comparator design in NCT06700343 is the standard bridging structure used to support both agencies with a single trial. Formal launch depends on resolution of Roche's Ocrevus patent portfolio, which extends beyond the ~2029 composition-of-matter cliff through formulation and dosing method claims [12].

CD20 is a protein sitting on the surface of B cells, a class of immune cells that make antibodies and coordinate other immune responses. Anti-CD20 antibodies bind CD20, tag those B cells for destruction by the immune system, and deplete circulating B cells for months. In multiple sclerosis, B cells drive part of the autoimmune attack that damages the myelin sheath insulating nerve fibers, so depleting them reduces relapses and slows disability progression. Ocrelizumab was approved in the US in 2017 for both relapsing and primary progressive MS based on the OPERA I/II trials, which showed significant reductions in annualized relapse rate versus interferon beta-1a [3], and the ORATORIO trial, which slowed disability progression versus placebo in primary progressive MS [4]. Ocrevus was the first drug ever approved for primary progressive MS [5]. The mechanism is validated across dozens of B-cell mediated diseases including rheumatoid arthritis and multiple lymphomas, where rituximab, ocrelizumab, and ofatumumab have all delivered efficacy. For a biosimilar, the mechanism question is closed. The scientific question is whether ABP 692's molecular fingerprint, glycosylation pattern, and Fc effector function match ocrelizumab closely enough that regulators accept clinical equivalence based on analytical and PK data.

NCT06700343 is a Phase 3 three-way PK/PD/safety comparability study enrolling 152 patients with relapsing-remitting MS [1]. Patients receive either ABP 692, US-sourced Ocrevus, or EU-sourced Ocrevus, following the label ocrelizumab induction schedule (two 300 mg IV infusions two weeks apart), with the primary PK window drawn after that initial dose [1]. The primary endpoint is area under the serum concentration-time curve from Day 0 to Day 15 following the first infusion [1]. Secondary endpoints cover additional PK parameters, B-cell depletion pharmacodynamics, immunogenicity (anti-drug antibody incidence), and safety. This is standard FDA/EMA biosimilar comparability design. It is not powered to detect differences in MS clinical outcomes like annualized relapse rate or MRI lesion counts, because that is not how biosimilars are approved. The three-way comparison lets Amgen use a single trial to support both US and EU regulatory submissions, cutting cost and time versus running separate bridging studies. Enrollment of 152 is small by MS efficacy trial standards but appropriate for a PK equivalence readout, where the statistical bar is showing that the 90% confidence interval of the geometric mean ratio between ABP 692 and Ocrevus falls within 0.80 to 1.25. Active-not-recruiting status since July 2026 indicates enrollment closed and patients are being followed through dosing and PK sampling [1].

Our model estimates a 59% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 85%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Analytical similarity is the biggest technical risk. Anti-CD20 mAbs depend on Fc-mediated effector function to kill B cells, which is sensitive to glycosylation. Small differences in fucosylation or galactosylation (sugar modifications attached to the antibody that control how efficiently it recruits immune cells to kill its targets) can shift antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity enough to trigger FDA questions. Amgen has passed this bar before with Riabni (rituximab biosimilar), so the internal capability is proven [2]. Immunogenicity is a related risk: if ABP 692 generates a different anti-drug antibody profile than Ocrevus, PK equivalence can fail even with matched molecular structure. Patent risk dominates the commercial picture. Roche has stacked patents on Ocrevus covering the extended dosing interval and manufacturing process, extending realistic launch beyond the ~2029 composition-of-matter cliff [12]. Amgen will need to challenge these through inter partes review and negotiate settlements. Commercial risk is real even post-launch, and made sharper by a crowded field: Samsung Bioepis, Sandoz, Biocad, and Celltrion all have ocrelizumab biosimilar programs in clinical development [11]. Multi-entrant biosimilar markets show faster and deeper net price erosion than first-entrant markets, so Amgen will not enjoy the pricing power of a solo launch. Biosimilar erosion in physician-administered oncology mAbs has been slower than pharmacy-dispensed biosimilars. Trastuzumab lost roughly 30% of its brand market share within a few years of biosimilar entry (a multi-entrant market analogous to what ocrelizumab will face), not the 80% erosion seen with small-molecule generics [8]. Ocrevus benefits from patient stickiness (twice-yearly infusions build routines), payer contracting, and Roche's September 2024 launch of Ocrevus Zunovo, a subcutaneous formulation with fresh IP that extends product life beyond IV biosimilar competition [9]. Interchangeability was not sought for ABP 692, so physicians must actively switch patients rather than pharmacies auto-substituting.

Worth watching, low-drama signal. Biosimilar programs from Amgen do not fail often at this stage. The interesting question is not whether this gets approved (probably yes, 2028 timeframe) but when Amgen can actually sell it and what share it captures in a crowded biosimilar entry class. Ocrevus generated approximately $7.5B for Roche in 2024 [6] and remains one of the largest single-product franchises in neurology. A biosimilar entrant taking 15 to 25% share over three years would represent a $1B to $2B annual opportunity, but with Samsung Bioepis, Sandoz, Biocad, and Celltrion all pursuing the same reference product [11], the price per unit will erode faster than a first-mover scenario. Realistic Amgen contribution likely falls at the lower end of that range, meaningful but not franchise-defining against Amgen's $36.75B in 2025 total revenue [10]. Key data points to watch: PK/PD readout expected late 2027, BLA acceptance in 2028, and any Genentech IP filings, IPR decisions, or Federal Circuit rulings on Ocrevus patents. Roche's September 2024 launch of Ocrevus Zunovo is a defensive move that shifts patients to a differently-patented subcutaneous formulation before IV biosimilars land [9]. Watch for Amgen developing a subcutaneous ABP 692 variant in response. On the science side, no readouts here will move the field. The interesting adjacent story is next-generation B-cell therapies (CD19 CAR-T, bispecifics) which threaten both Ocrevus and its biosimilars if they demonstrate durable remission in MS. Check back after the 2027 PK readout and any Roche versus Amgen patent filings.